We recently demonstrated that electroporation enhances transfection in a mouse wound-healing model. Keratinocyte growth factor (KGF) is an inducer of epithelial cell proliferation and differentiation and has been shown to be under expressed in the wounds of diabetic individuals. We hypothesized that KGF delivered into an excisional wound via naked DNA injection with subsequent electroporation would be a novel and potentially effective method to enhance wound closure in a diabetic mouse model. ELISA assays confirmed production of KGF protein in cultured mouse cells and RT-PCR assays confirmed KGF mRNA in skin samples taken from mice. In all, 32 genetically diabetic mice were given two identical excisional wounds of their dorsum and split into two groups with one group receiving KGF DNA injection and electroporation with the other group receiving no treatment. Over 90% of wounds healed in the presence of KGF and electroporation versus 40% in the untreated group by day 12. Histological analysis of the wounds demonstrated that untreated wounds contained microulcers with thin or incomplete epithelium with unresolved inflammation as compared to treated wounds where intact and mature epithelium was observed. Taken together these findings suggest that a single injection of KGF DNA encoded on a plasmid coupled with electroporation improves and accelerates wound closure in a delayed wound-healing model.
Introduction
Growth factors or cytokines are proteins that act as regulators and co-coordinators of various cellular processes. The first discovery of a growth factor came in 1962 with the purification of a protein from mouse salivary glands and the observed effect on nerve cells. 1, 2 The importance of growth factors during the woundhealing process cannot be overstated as they act as triggers that stimulate sedentary cell lineages to proliferate and ultimately lay down new cells at the wound site. There are over 18 different types of growth factors that have been found at the wound site including EGF, TGF-a, FGF 1-10, keratinocyte growth factor (KGF) (A.K.A. FGF7), PDGF, IGF-1, VEGF, TGFb1-3, CTGF, activin, IL-1a and IL-b, TNF-a, TGF-b and HIF1-a. 3 KGF is a 26-28 kDa protein of the fibroblast growth factor group. 4 KGF is produced in fibroblasts, endothelial cells and smooth muscle cells but not in epithelial cells. 5 Recent in vivo and in vitro studies have shown that KGF is essential for skin morphogenesis and epithelial cell differentiation through stimulation of epithelial and mesenchymal factors. 6 Exogenous application of growth factors has improved the healing process in experimental settings. Recombinant PDGF (Regranex, Ortho-McNeil) has been approved by the FDA as a topically applied gel that acts biologically similarly to endogenous PDGF by promoting the chemotactic recruitment and proliferation of cells involved in wound repair. Regranex is FDA approved for the treatment of diabetic neuropathic ulcers. 7 Enhanced healing was observed with daily topical application of PDGF in the clinical trials. But the effect was minimal with a marginal increase in the incidence of complete healing as compared to a placebo gel (50 versus 37%).
Topically applying growth factors to wounds has major drawbacks; for example, in our animal study of exogenously applied FGF-1 it was necessary to repeatedly administer large amounts of recombinant FGF-1 to achieve a significant improvement in wound healing. 8 Large amounts of FGF-1 were required due to the short half-life of the reagent raising the costs and complexity of potential therapeutic use; furthermore the wound eschar can block access to the wound by growth factors. Although many reports exist on the topical application of growth factors on wounds in humans there are only a few reports in which a positive effect was noted. 9 As a solution to the problems associated with topical application of growth factors, gene therapy is being proposed as a method to continuously supply growth factors to the wound. Many gene therapy approaches have been tested to transfect cells with DNA encoding growth factors. Simply injecting naked DNA into the wound required repeated injections and high DNA loads both of which impaired wound healing. 10 One group has recently reported remarkable success with injection of naked DNA encoding TGF-b1, but our experience has been less encouraging with that approach. 10, 11 Another approach is the gene gun wherein particle-mediated transfer of cDNA is utilized as the plasmid vector is coated onto gold beads and fired through the skin. But the gene gun results in highly variable gene expression. [12] [13] [14] Although virally mediated gene delivery has high transfection efficiency there are serious concerns about its safety and potential pathogenicity. 15 Our laboratory has been investigating the possibility of using naked DNA injection coupled with electroporation. Electroporation has been shown to improve cellular uptake of DNA by more than 10-fold over injection alone, and has exhibited none of the safety concerns associated with viral gene delivery. 16 Electroporation is the application of an electrical field across a tissue or cell. It is believed that if the applied electrical field is of sufficient strength and intensity the dielectric index of the cell membrane is exceeded, causing transient pores to open in the lipid bilayer thereby increasing the permeability of the cells to large molecules. 16 We have demonstrated that by optimization of the electroporation parameters transfection efficiency can be improved in murine cutaneous wounds. 17 For the current study, we used the diabetic mouse BKS.Cg-m homozygous (Lepr db /Lepr db ) as a wound-healing model. Wound healing in diabetes is markedly slower than normal, and diabetic individuals have been shown to have a decreased and delayed expression of KGF. 18 In addition to decreased levels of growth factors is increased proteolytic activity leading to the destruction of growth factors are involved in the pathogenesis of impaired healing in diabetics. 19 We hypothesized that supplying supplemental KGF to wounds in these animals would improve wound healing.
Results

Selection of the gWIZ KGF expression vector
Human KGF-1 was cloned into three different expression vectors each utilizing the CMV promoter for transcription. A polyadenylation tail was provided by SV40. Expression of human KGF-1 protein was analyzed by an enzyme-linked immunosorbant assay (ELISA) after transfection into the murine cell line NIH3T3. Supernates from NIH3T3 cells expressing KGF-1 were applied to ELISA plates coated with human KGF-1 antibody and compared to known standards. The vector gWIZ-KGF was selected because it was the most productive of the three (Figure 1 ). pCDNA3.1/GS-KGF also efficiently expressed KGF although not as abundantly as gWIZ-KGF ( Figure 1 ). The larger episomal vector pCEP4-KGF was very inefficient at expressing KGF protein, therefore its use was discontinued ( Figure 1 ).
Murine KGF-1 RNA detected in mouse skin
We used specific primers to detect plasmid encoded KGF-1 mRNA purified from transfected mouse skin (Figure 2a and b). To confirm that endogenous KGF mRNA was not detected by our primers we transfected some animals with empty vector (Figure 2a and b, lanes 1 and 2). Two different doses of KGF-1 plasmid DNA (25 and 100 mg) were injected into three animals, respectively. At 25 mg plasmid load, KGF mRNA was detected in one of three animals ( Figure 2a , lanes 4-6), however, at 100 mg plasmid load three of three animals yield a positive result (Figure 2b , lanes 4-6). DNA size markers are denoted in lane M and the KGF-1 PCR product size of 600 bp is highlighted.
Effect of electroporation on wounds
As a control we tested the effect of electroporation on wounds without combining it with a plasmid DNA expression vector. It was possible that electroporation might damage tissue and impair wound healing; or alternatively electroporation might induce faster healing. We found that electroporation alone did not have a significant impact on wound healing although there was a tendency for faster closure in the presence of electroporation ( Figure 3) .
Effect of KGF-1 plasmid DNA with or without electroporation on wound closure
To assess the effect of electroporated plasmid DNA encoding human KGF-1 we initially compared this treatment against completely untreated mice. As can be seen in Figure 4 , wounds that had been treated with KGF-1 and electroporation closed faster than untreated wounds. Wounds in treated mice were 38% smaller than untreated wounds at day 12 (220774 versus 577790 pixels, Po0.05) (Figure 4a ). At the end of the experiment wounds were examined and deemed to be healed if a complete layer of epithelium covered the wound Wound-healing enhancement with electroporation of growth factor DNA G Marti et al site. According to this criterion 92% of treated wounds had healed as compared to 40% of untreated wounds (Figure 4b ).
An additional experiment was designed to analyze the effect of electroporation on wounds injected with KGF-1 plasmid DNA. In this study all mice (32) were injected with DNA although only half 16 were electroporated. From Figure 5 , it can be noted that at the early stages of the experiment (day 5) the wound sizes were not significantly different, however, at days 10 and 12 the wound areas of the electroporated group were more than 50% smaller than the nonelectroporated group indicating a positive healing effect in the presence of electroporation.
Histologic assessment of the quality of wound healing
Histological assessment was performed using a grading scale for quality of epithelialization. Figure 5 shows examples of wounds at each histologic grade. A Grade 1 sample has an incomplete epithelium with microulcers, Grade 2 has thin epithelium, unresolved inflammation and hemorrhage, Grade 3 has intact but unreticulated epithelium and Grade 4 has reticulated thick mature epithelium. Wounds from KGF-1/EP-treated animals were graded higher than the untreated group by observers blinded to the protocol (3.370.4 versus 1.570.1, Po0.05).
Discussion
In diabetic patients the ability to heal wounds is severely impaired. 18, 19 Wound healing impairment in the genetically diabetic mouse reflects similar problems such as prolonged inflammation, impaired neovascularization and decreased synthesis of collagen. 20 Expression profiles of various growth factors are also aberrant in the diabetic mouse with KGF-1 and FGF induction being premature, delayed or absent as compared to a healthy mouse. 18 The failure of diabetic mice to produce timely increases of FGF and KGF-1 levels led us and others to attempt to remedy the situation by applying growth factors or using gene therapy. Topical application has had very little clinical success. The eschar blocks entry and proteases destroy the growth factors. Wound-healing enhancement with electroporation of growth factor DNA G Marti et al
Gene therapy has the potential to produce growth factors in the wound or surrounding tissues where they can be active and continually replenished. We initially used direct injections of naked DNA plasmid vector for FGF. 8 This required massive and repeated dosing with plasmid DNA (100 mg delivered in nine daily doses). We have found that these large applications of plasmid DNA were detrimental to wound healing. 10 In the present study, we utilized electroporation to improve transfection efficiency so that a single dosing regimen could be utilized and a much smaller application of DNA would be required. Drabick et al 16 demonstrated that electroporation enhances gene uptake into various cells in the cutaneous layer in mouse and pig. We utilized the skin specific electroporation parameters that we identified in our earlier work. 17 In that study, we used a luciferase expressing plasmid to assess various electrodes, voltages, pulse durations and intervals to find an optimal set for cutaneous transfection. The parameters that worked best include six pulses at 1800 V with duration of 100 ms and an interval of 125 ms, delivered by a multiple pin type electrode. 17 Consistent with our results it has been demonstrated that the relatively small cells of the dermis require high voltage, short duration pulses in contrast to the larger duration lower voltage which is effective in muscle where cells are larger. 16 An additional recent study confirmed that cell age and type is an important factor when considering electroporation therapy as it has been demonstrated that older mice transfect less efficiently than younger mice. 22 We use relatively young mice of a similar age throughout our study.
Having an efficient transfection protocol we then used an ELISA to compare the productivity of various plasmid constructs expressing KGF transfected into a murine NIH3T3 fibroblast cell line. The most productive plasmid was chosen for this study. Next we identified that the KGF expression vector has the ability to produce KGF in vivo using RT-PCR. We were then ready to start wound-healing experiments.
When the gWIZ-KGF plasmid was applied to fullthickness cutaneous wounds in diabetic mice the rate of closure of the wounds was increased. This increase was seen in comparison to untreated wounds as well as in comparison to wounds treated with KGF alone without electroporation.
We assessed the quality of wound healing using a histologic grading system with two blinded observers. Using a method developed in this laboratory observers graded each wound based on select criteria. After grading 64 wounds it was apparent that the quality of the wounds after treatment of KGF-1/EP was significantly better than with no treatment showing a more mature and complete epithelium.
Although more work needs to be done we believe this study supports gene therapy as a potential tool to accelerate wound healing in a healing impaired environment such as a diabetic wound. The future of gene therapy for wound healing will require consistent and safe methods to deliver DNA to the site of interest resulting in a beneficial effect. We have shown that direct injection of naked DNA coupled with electroporation does improve wound healing. This modality has the potential to be the safe and consistent method for gene therapy on wound healing.
Materials and methods
Plasmids
Plasmid pCDNA3.1/KGF-1 was obtained from Invitrogen (Carlsbad, CA, USA). Using gene-specific PCR primers incorporating restriction enzyme sites for Pst1 and BamH1, KGF-1 was PCR amplified from pCDNA3.1/KGF and ligated into the corresponding restriction enzyme sites in gWIZ (Gene Therapy Systems, San Diego, CA, USA). All plasmids were purified using an endotoxin free plasmid purification kit (Qiagen, Valencia, CA, USA) following manufacturer's instructions. Plasmid DNA was stored at À201C.
PCR
Conventional PCR was performed using a standard PCR kit from Invitrogen (Carlsbad, CA, USA) and carried out according to manufacturer's instructions.
PCR primers:
OJW007: 5 0 -AACTGCAGATGCACAAATGGAT-3 0 and OJW004: 5 0 -TTAAGTTATTGCCATAGGAAG-3 0 .
Cell culture and transfection NIH3T3 cells were obtained from the ATCC (Manassas, VA, USA) and maintained in DMEM supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) in a humidified incubator at 371C with 5% CO 2 . NIH3T3 cells were seeded in six-well plates at 2 Â 10 5 cells/well. DNA constructs were incubated with lipofectamine (Invitrogen, Carlsbad, CA, USA) at room temperature for 30 min. Prior to transfection cells were rinsed in Optimem (Invitrogen, Carlsbad, CA) before the lipid-DNA complex was added and incubated together at 371C for 5 h. Cell extracts were harvested 24-48 h after transfection and assayed for presence of human KGF-1 protein by ELISA.
ELISA KGF-1 standards and KGF-1 human antibody were obtained from R&D Research Systems (Minneapolis, MN, USA). All subsequent steps in the ELISA were performed according to manufacturer's instructions. A standard curve of known KGF-1 concentration was plotted against absorbance. Cell culture extract samples were compared to the standard curve allowing human KGF-1 protein concentration to be determined.
RT-PCR
In a separate experiment 25 or 100 mg of pCDNA3.1-KGF plasmid DNA were intradermally injected into Balb-C mice. After 17 days mice were killed and skin tissue removed and frozen in liquid nitrogen. Tissue was homogenized and then purified using a RNA isolation kit (Qiagen, Valencia, CA, USA). RNA was purified according to manufacturer's instructions. Aliquots of RNA were used in a RT-PCR reaction employing a RT-PCR kit from Qiagen (Valencia, CA, USA). Primers were designed to ensure only exogenously expressed murine KGF-1 mRNA would be detected yielding a 600 bp product Plasmid specific KGF-1 primers used were:
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Plasmid administration
Female 6-8-week-old BKS.Cg-m. Lepr db/db mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). All procedures were approved by the Johns Hopkins University Animal Care and Use Committee. Animals were first anesthetized with an intraperitoneal injection of 0.025 ml/g of ketamine before their dorsum was shaved and two symmetrical full-thickness excisional wounds were created using a 5 mm punch biopsy punch on the left and right side. Plasmid DNA (50 mg) in 50 ml of PBS was injected intradermally both anterior and posterior to each wound exposing the wound to a total concentration of 100 mg of DNA. The resulting skin blebs confirmed intradermal delivery of the plasmid. Wounds were left undressed and animals were housed individually.
Electroporation
Animals were electroporated at the site of injection within 2 min of plasmid administration using a square wave electroporator (ECM 830, BTX Genetronics, San Diego, CA, USA). A custom designed pin electrode, consisting of two 10 mm rows of parallel acupuncture needles separated by 5 mm was used to apply the electroporation voltage. Six square wave pulses were administered at an amplitude of 1800 V for a duration of 100 ms, and an interval between pulses of 125 ms. Wound areas were measured at days 5, 10 and 12.
Wound-healing measurements
On days 5, 10 and 12 wound eschar was carefully removed and the unepithelialized wound border was traced in situ onto clear acetate paper. Images were digitized at 600 dpi (Visioneer Paperport 6000, Visioneer, Frement, CA, USA) and wound areas were calculated using image analysis software based on NIH image (Scion Image, Frederick, MD, USA). Areas were expressed as a pixel count.
Histologic assessment
On day 12, the wounds were excised and fixed in 10% formalin. Fixed skin samples were paraffin embedded and 5 mm sections prepared, mounted and stained with hematoxylin and eosin ( Figure 6 ). Histologic sections from each wound were analyzed and graded by two examiners who were blinded as to the identity of each Figure 6 Hematoxylin and eosin stained and sectioned mouse wound tissue. Typical wounds from grades 1 to 4 are presented.
Wound-healing enhancement with electroporation of growth factor DNA G Marti et al sample. Histological assessment was done with a grading scale for quality of epithelialization (Grade 1, incomplete epithelium with microulcers; Grade 2, thin epithelium, unresolved inflammation; Grade 3, intact, not reticulated epithelium; Grade 4, reticulated mature epithelium) ( Figure 7 ).
Statistical analysis
Results are presented as means7s.e.m. Differences in means between groups were analyzed for significance using Student's t-test or ANOVA as appropriate. Wound-healing enhancement with electroporation of growth factor DNA G Marti et al
